We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
+57.48%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$514M
AUM Growth
-$7.79M
(-1.5%)
Cap. Flow
-$48M
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
56.23%
Holding
206
New
96
Increased
32
Reduced
19
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRNE
Sorrento Therapeutics, Inc.
SRNE
|
+$11.2M |
| 2 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$11.1M |
| 3 |
ASXC
Asensus Surgical, Inc.
ASXC
|
+$8.33M |
| 4 |
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
|
+$8.2M |
| 5 |
WIMI
WiMi Hologram Cloud
WIMI
|
+$8.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$31.5M |
| 2 |
AstraZeneca
AZN
|
+$18.2M |
| 3 |
Moderna
MRNA
|
+$12.1M |
| 4 |
XWELL
XWEL
|
+$6.41M |
| 5 |
CEL-SCI Corp
CVM
|
+$3.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13.44% |
| 2 | Technology | 2.48% |
| 3 | Consumer Staples | 2.16% |
| 4 | Communication Services | 1.48% |
| 5 | Financials | 0.89% |
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q1 2021 Portfolio in Review
As of Q1 2021, Sabby Management held 206 positions worth $514M, down 1.5% from $522M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Sabby Management withdrew a net $48M in Q1 2021, closing 50 positions and reducing 19 holdings. Its most notable exit was Biogen, an estimated $31.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 13% of assets, down from 18% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Sabby Management opened a new position in Sorrento Therapeutics, Inc. worth $8.81M.
- Sabby Management's largest Q1 2021 buy was Sorrento Therapeutics, Inc.: 1,064,933 shares worth $8.81M.
- Sabby Management added most to Odonate Therapeutics, Inc. Common Stock in Q1 2021, an estimated $11.1M increase.
- Sabby Management's biggest Q1 2021 reduction was AVEO Pharmaceuticals, Inc., cutting an estimated $494K.
- Sabby Management fully exited Biogen in Q1 2021, selling an estimated $31.5M.
- Sabby Management's ten largest holdings make up 56% of its $514M portfolio in Q1 2021.
- Sabby Management opened 96 new positions and closed 50 in Q1 2021.
- Sabby Management's portfolio value fell 1.5% quarter-over-quarter to $514M.
Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.